Eprogen

According to Matthew Kuruc, COO of PIN member ProFact Proteomics, the network aims to help smaller firms offer complete solutions similar to those increasingly provided by large instrument vendors and to popularize non-mass spec-based proteomics workflows.

Although it's too early to announce biopharma partners, the 13 companies involved in the network are hoping that their collective skills and specialties will attract companies interested in developing drugs targeted to specific proteomic markers in patients.

The group aims to provide solutions for all stages of proteomics research and address "critical unmet needs in biomarker and drug target discovery, personalized medicine, drug profiling, and selective reaction monitoring."

Over the past week, OGT acquired protein-array maker Sense Proteomic, Aushon bought Thermo's SearchLight protein-array business, and Gentel and Eprogen allied to help drug makers identify new autoantibody biomarkers.

Industry Briefs

Premium

Gentel, Eprogen, Novozymes, Proteome Sciences, Pepsca, Advanced Proteome Therapeutics, AnaSpec

Gentel and Eprogen will combine their respective technologies to make whole proteome microarrays for identifying new autoantibody biomarkers.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.